GREGORY A POLAND, M.D.
Osteopathic Medicine at 1 St, Rochester, MN
License number
Minnesota 26502
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
200 1St St SW, Rochester, MN 55905
Phone
(507) 284-2511
Organization information
See more information about GREGORY A POLAND at bizstanding.comGregory Poland MD
200 1 St SW, Rochester, MN 55905
Industry:
Internist
Site:
Phone:
(507) 284-2511 (Phone)
Description:
There are 28 doctors at this site. Surgery is not performed at this site.
Gregory Arthur Poland
Mayo Clinic - Gregory A Poland MD
200 1 St SW #W4, Rochester, MN 55905
Categories:
Physicians & Surgeons
Phone:
(507) 284-2511 (Phone)
Gregory A Poland Associates
1079 Plummer Ln SW, Rochester, MN 55902
Industry:
Business Services
Owner:
Gregory A. Poland (Owner)
Professional information
Gregory A Poland, Rochester MN
Specialties:
Internist
Address:
200 1St St Sw, Rochester, MN 55905
Education:
Southern Illinois University, School of Medicine - Doctor of Medicine*
Abbott Northwestern Hospital - Residency - Internal Medicine*
Abbott Northwestern Hospital - Residency - Internal Medicine*
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine*
Gregory Arthur Poland, Rochester MN
Specialties:
Internal Medicine
Work:
Mayo Medical School
200 1St St Sw, Rochester, MN 55905
200 1St St Sw, Rochester, MN 55905
Education:
Southern Illinois University (1980)
Dr. Gregory A Poland, Rochester MN - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
Mayo Clinic
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
Certifications:
Internal Medicine, 1985
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Mayo Clinic
200 1St St SW, Rochester 55905
Mayo Clinic Methodist Hospital
201 West Center St, Rochester 55902
200 1St St SW, Rochester 55905
Mayo Clinic Methodist Hospital
201 West Center St, Rochester 55902
Education:
Medical School
Southern Illinois University School Of Medicine
Graduated: 1980
Abbott Northwestern University Minn
Graduated: 1981
Graduated: 1984
Southern Illinois University School Of Medicine
Graduated: 1980
Abbott Northwestern University Minn
Graduated: 1981
Graduated: 1984
Vaccinia Virus Polypeptides
US Patent:
2012007, Mar 29, 2012
Filed:
Aug 31, 2011
Appl. No.:
13/222862
Inventors:
Gregory A. Poland - Rochester MN, US
Inna G. Ovsyannikova - Rochester MN, US
Kenneth Lee Johnson - Rochester MN, US
Inna G. Ovsyannikova - Rochester MN, US
Kenneth Lee Johnson - Rochester MN, US
International Classification:
A61K 39/285, A61P 37/04, A61P 31/20, C07K 7/06, C07K 7/08
US Classification:
4241861, 530328, 530327, 530326
Abstract:
This document provides methods and materials related to polypeptides present in a vaccinia virus (e.g., polypeptides that can be isolated from naturally processed and presented class I polypeptides originating from vaccinia virus, a member of the Orthopoxvirus family). For example, methods for generating a vaccine comprising one or more of vaccinia virus polypeptides disclosed herein for preventing or treating Orthopoxvirus infection are provided. In addition, kits related to the use of vaccinia polypeptides are provided.
Naturally Processed Measles Virus Peptides Eluted From Class Ii Hla Molecules
US Patent:
2006012, Jun 15, 2006
Filed:
Nov 4, 2005
Appl. No.:
11/266957
Inventors:
Gregory Poland - Rochester MN, US
Inna Ovsyannikova - Rochester MN, US
David Muddiman - Raleigh NC, US
Kenneth Johnson - Rochester MN, US
Inna Ovsyannikova - Rochester MN, US
David Muddiman - Raleigh NC, US
Kenneth Johnson - Rochester MN, US
International Classification:
A61K 39/00, C12Q 1/68, C07H 21/04, C07K 14/74
US Classification:
424185100, 435069300, 435320100, 435325000, 435006000, 530350000, 536023500
Abstract:
A preparation of peptides eluted from class II HLA molecules is disclosed. Methods of decreasing measles infections comprising inoculating human patients with a vaccine comprising one or more of the peptides and methods of diagnosing measles infections or immunity comprising analyzing human patients for the presence of one or more of the peptides or antibodies to the peptide(s) are also disclosed.
Naturally Processed Measles Virus Peptides Eluted From Class Ii Hla Molecules
US Patent:
2006003, Feb 16, 2006
Filed:
Apr 28, 2005
Appl. No.:
11/116682
Inventors:
Gregory Poland - Rochester MN, US
Inna Ovsyannikova - Rochester MN, US
David Muddiman - Cary NC, US
Kenneth Johnson - Rochester MN, US
Inna Ovsyannikova - Rochester MN, US
David Muddiman - Cary NC, US
Kenneth Johnson - Rochester MN, US
International Classification:
A61K 39/12, C07H 21/04, C12N 7/00, C07K 14/12
US Classification:
424186100, 435069300, 435235100, 435325000, 530350000, 536023720
Abstract:
A preparation of peptides eluted from class II HLA molecules is disclosed. Methods of decreasing measles infections comprising inoculating human patients with a vaccine comprising one or more of the peptides and methods of diagnosing measles infections or immunity comprising analyzing human patients for the presence of one or more of the peptides or antibodies to the peptide(s) are also disclosed.
Naturally Processed Measles Virus Peptides From Class Ii Hla Molecules
US Patent:
8221762, Jul 17, 2012
Filed:
Jul 22, 2009
Appl. No.:
12/507163
Inventors:
Gregory A. Poland - Rochester MN, US
Inna G. Ovsyannikova - Rochester MN, US
David C. Muddiman - Raleigh NC, US
Kenneth L. Johnson - Rochester MN, US
Inna G. Ovsyannikova - Rochester MN, US
David C. Muddiman - Raleigh NC, US
Kenneth L. Johnson - Rochester MN, US
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
A61K 39/38, A61K 38/00, G01N 33/53
US Classification:
4241841, 4242111, 4241851, 4241861, 530324, 435 71
Abstract:
A preparation of peptides eluted from class II HLA molecules is disclosed. Methods of decreasing measles infections comprising inoculating human patients with a vaccine comprising one or more of the peptides and methods of diagnosing measles infections or immunity comprising analyzing human patients for the presence of one or more of the peptides or antibodies to the peptide(s) are also disclosed.
Peptide Originating From Vaccinia Virus
US Patent:
7622120, Nov 24, 2009
Filed:
Apr 20, 2007
Appl. No.:
11/738210
Inventors:
Gregory A. Poland - Rochester MN, US
Inna G. Ovsyannikova - Rochester MN, US
David C. Muddiman - Raleigh NC, US
Kenneth L. Johnson - Rochester MN, US
Inna G. Ovsyannikova - Rochester MN, US
David C. Muddiman - Raleigh NC, US
Kenneth L. Johnson - Rochester MN, US
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
A61K 39/38, A61K 39/00, A61K 39/12, A61K 39/275, C07K 14/00, A61K 39/155
US Classification:
4241861, 4242321, 4241841, 4241851, 530300
Abstract:
A vaccine for preventing or treating Orthopoxvirus infection that induces a protective or therapeutic immune response, wherein the vaccine comprises (1) an amino acid sequence of 20 amino acid or less (preferably 12 amino acid or less and most preferably 11 amino acid or less) of the formula X-SEQ ID NO:1-X, wherein Xand Xare peptides of 0-11 amino acid in length comprising either native or non-native amino acid sequences, (2) an antigen-presenting cell pulsed with the peptide, or (3) a cell sensitized in vitro to the peptide is disclosed.
Vaccinia Virus Polypeptides
US Patent:
2014005, Feb 20, 2014
Filed:
Aug 23, 2012
Appl. No.:
13/593365
Inventors:
Gregory A. Poland - Rochester MN, US
Richard B. Kennedy - Rochester MN, US
Richard B. Kennedy - Rochester MN, US
Assignee:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN
International Classification:
A61K 39/285, C07K 14/005
US Classification:
4241861, 530326
Abstract:
This document provides methods and materials related to polypeptides present in a vaccinia virus (e.g., membrane proteins such as vaccinia virus B5R, L1R, A33R, or A27L polypeptides). For example, methods for generating a vaccine comprising one or more of vaccinia virus polypeptides disclosed herein for preventing or treating Orthopoxvirus infection are provided. In addition, kits related to the use of vaccinia polypeptides are provided.